Jyong Biotech Ltd.

Stage 4 · Declining · week 4

As of Oct 22, 2026, Jyong Biotech is in Stage 4, the downtrend phase, now in week 4 (since Oct 1, 2026). It closed at $1.74, 97.1% below its 52-week high and below its 200-day average, which is falling.

$1.74

-7.45% today

$132M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MENS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-06-17 → 2026-10-22

S? 41w

S1 10w

2025-06-172026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 4w → S1 3w → S4 2w → S1 1w → S4 6w → S1 10w → S4 3w current

Total tracked: 70 weeks across 8 stage runs.

MENS among Biotechnology540th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…540	MENSJyong Biotech Ltd.	Stage 4 · wk 4	4	−18.7%

vs 52W High

-97.1%

$1.46 lo$60.80 hi

97.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.3%

200 DMA: $2.21 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

3.16x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.7%

-26.3%

-23.3%

YTD

-49.0%

-97.1%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 4 · Vol 3.16x

2026-10-21S4

Wk 3 · Vol 0.53x

2026-10-20S4

Wk 3 · Vol 0.66x

2026-10-19S4

Wk 3 · Vol 1.09x

2026-10-16S4

Wk 3 · Vol 1.00x

2026-10-15S4

Wk 3 · Vol 3.61x

2026-10-14S4

Wk 2 · Vol 0.82x

2026-10-13S4

Wk 2 · Vol 0.56x

2026-10-12S4

Wk 2 · Vol 0.48x

2026-10-09S4

Wk 2 · Vol 0.88x

2026-10-08S4

Wk 2 · Vol 0.92x

2026-10-07S4

Wk 1 · Vol 0.61x

Moving averages & range

50 DMA

$2.10

200 DMA

$2.21

52W High

$60.80

52W Low

$1.46

5D Low

$1.74

Resistance levels (recent highs)

20d High

$2.18

60d High

$2.39

120d High

$2.71

250d High

$60.80

Next resistance

+25.3%

to 20d High

Dividend Yield

0.00%

P/B -5.2

Jyong Biotech: quick answers

What stage is Jyong Biotech in?

As of Oct 22, 2026, Jyong Biotech (MENS) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Jyong Biotech in an uptrend?

No. Jyong Biotech is in a Stage 4 downtrend. It trades 21.3% below its 200-day average, which is falling.

How far is Jyong Biotech from its 52-week high?

Jyong Biotech closed at $1.74 on Oct 22, 2026, 97.1% below its 52-week high of $60.80. Its 52-week low is $1.46.

How has Jyong Biotech performed over the past year?

As of Oct 22, 2026, Jyong Biotech is down 97.1% over the past year and down 49.0% so far in 2026.

Which sector and industry is Jyong Biotech in?

Jyong Biotech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.